Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Novel MCH antagonists in early development at Aventis

Oct. 1, 2004

Novel glycogen phosphorylase inhibitors developed by Aventis team

Oct. 1, 2004

New targeted delivery methodology for male contraception

Sep. 30, 2004

Teijin patent covers new vitamin D analogues for bone disorders

Sep. 30, 2004

New MCH-1R antagonists and their use in obesity, diabetes, etc.

Sep. 30, 2004

Nastech and Merck & Co form alliance over PYY3-36 Nasal Spray

Sep. 30, 2004

FibroGen licenses FG-2216 to Yamanouchi for Japan

Sep. 29, 2004

Chugai claims new vitamin D analogues and their use in calcium metabolism disorders

Sep. 29, 2004

Kissei presents new SGLT-1 inhibitors for diabetes and related disorders

Sep. 29, 2004

New DPP-IV inhibitors prepared and tested by Sanwa Kagaku scientists

Sep. 29, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Recludix’s first-in-class STAT6 inhibitor shows efficacy in atopic dermatitis
BioWorld Science
Researchers from Recludix Pharma Inc. reported preclinical efficacy data on REX-8756 (SAR-448755), a first-in-class orthosteric STAT6 inhibitor in models of...